Tag: Prescription Drugs

Decrease seen in mean monthly headache days and reduction in Migraine Disability Assessment scores

Rate of combined clinically significant or severe hypoglycemia significantly lower with efsitora versus glargine

Total adverse events of heart failure or all-cause mortality were reduced with empagliflozin, regardless of kidney function

All three doses of orforglipron superior to placebo with respect to primary end point of change in HbA1c from baseline to week 40

Sustained reduction seen in body weight versus placebo for adults aged 18 to 75 with overweight or obesity, without diabetes

Defect-free quadruple medication therapy significantly improved at discharge, 30 days in patients with heart failure with reduced ejection fraction

0.5 percent with obesity were prescribed an obesity medication in 2023; 83 percent of prescriptions received by teens with severe obesity

Greater reduction in urinary albumin-to-creatinine ratio seen for combination versus either agent alone

Dapagliflozin results in more patients with improved or resolved MASH without worsening of fibrosis, improved fibrosis without worsening of MASH

Risk for major adverse cardiac and cerebrovascular events lower compared with aspirin monotherapy for patients who undergo PCI and discontinue DAPT